AltiBio is dedicated to developing innovative therapies aimed at providing relief for individuals suffering from rare and severe diseases. Founded in 2017, the company is driven by a mission to transform the lives of patients through the development of orphan therapeutics. Their current pipeline includes several projects, notably ATB226, ATB227, and ATB228, which are in various stages of development. The team at AltiBio has a strong background in successfully navigating the clinical, regulatory, and commercial landscapes, which positions them well to advance their lead product candidate, ATB226, through the necessary stages of development.

The company is currently focused on the IND enabling activities for ATB226, with plans to initiate Phase 1 development pending the acquisition of Series B funding. AltiBio's commitment to leveraging compelling data from their research underscores their strategic approach to bringing new therapies to market. By building on their previous successes, AltiBio aims to make significant advancements in the treatment of rare diseases, ultimately improving the quality of life for affected patients and their families.

United States

AltiBio, Inc. is a San Francisco Bay Area biopharmaceutical company founded in early 2017 to bring relief to people living with rare and severe diseases. The management team has extensive experience developing and commercializing orphan therapeutics. The company currently has three projects in development, with two molecules. More news will soon be coming as the company nears its next big milestone...

AltiBio

Company Details